We recently published a list of Billionaire Mario Gabelli’s 10 Large-Cap Stock Picks with Huge Upside Potential. In this ...

In this article, we are going to look at where Regeneron ... shift in the Federal Reserve’s interest rate policies is a key driver of this upturn. Biotech is sensitive to changing rate patterns ...

Now, the company made a big shift to a more shareholder-centric approach by initiating their first-ever quarterly dividend of $0.88 per share in Q1 of this year. What is more, Regeneron has ...

Regeneron has leveraged its monoclonal antibody ... but over the next few years we expect most of its sales to shift to long-acting Eylea HD, a higher-dose formulation. Starting in 2025, the ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles ... Schleifer attributed the shift to more patients using off-label bevacizumab—aka Avastin—to treat their retinal ...